EMA Withdrawn: Celvapan (whole virion influenza vaccine, inactivated containing antigen of strain A/California/07/2009 (H1N1)v) — Nanotherapeutics Bohumil, s.r.o.

View source ↗

Summary

The EMA lists Celvapan as withdrawn from the market; it was a whole virion influenza vaccine against H1N1, with Nanotherapeutics Bohumil, s.r.o. as the MAH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Disease Outbreaks

Drugs mentioned

• Celvapan (Influenza A/H1N1 vaccine (cell-derived))

Snippet

Status: Withdrawn. Therapeutic area: Disease Outbreaks;Influenza, Human;Immunization. MAH: Nanotherapeutics Bohumil, s.r.o.. Decision date: 30/11/2015